FLD-103

N/A

Report date: 2026/05/07 20:00:36

NME

Base Information

Drug NameFLD-103

Drug Alias NameFLD-103

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Peptide-oligonucleotide ConjugateSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) > Peptide-oligonucleotide ConjugateSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionZinc finger protein GLI1 inhibitors

TargetsZinc finger protein GLI1

Therapy Area/IndicationsCarcinoma, Basal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesFeldan Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesFeldan Therapeutics

Inactive CompaniesN/A

Active IndicationsCarcinoma, Basal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A